Generative biology platform intended to invent new drugs across protein modalities and protein therapeutics. The company's platform leverages machine learning to understand the genetic code underlying the function of proteins to rapidly generate antibodies, peptides, enzymes, cell and gene therapies to meet any therapeutic need, enabling biologists to bring radically new medicines to patients.
Our machine learning algorithms analyze hundreds of millions of known proteins, looking for statistical patterns linking amino acid sequence, structure, and function. Using these learned statistical patterns, we generate custom protein therapeutics—from short peptides to complex antibodies, enzymes, gene therapies, and yet-to-be-described protein compositions.
Total Funding: $420 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Generate Biomedicines
Senior Data Engineer, Machine Learning Ops
Cambridge, MA
Machine Learning Engineer
Cambridge, MA
Data Scientist
Cambridge, MA
Data Engineer
Cambridge, MA
Senior Technical Recruiter, Talent Acquisition
Cambridge, MA
